Golden Helix Named to the 2020 Inc. 5000 List of Fastest-Growing Private Companies for our Second Consecutive Year!
August Newsletter
Golden Helix Named on Inc 5000 List of Fastest-Growing Private Companies for 2nd Consecutive Year

Golden Helix Named on Inc 5000 List of Fastest-Growing Private Companies for 2nd Consecutive Year 
 By Andreas Scherer, PhD 
 President & CEO

Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. Today, we have been included in the esteemed Inc. 5000 list of rapidly growing American companies. Out of the 6 million business in the United States, Golden Helix has been honored with a spot in the annual list for the 2nd consecutive year... Read More

Golden Helix Announces New Workflow for the Interpretation and Reporting of Copy Number Variants in Concordance with the Recently Updated ACMG Guidelines
By Andreas Scherer, PhD 
 President & CEO

Over the last several months, our team has been diligently working on a new guided workflow that will allow clinical labs to implement these guidelines consistently and efficiently. This workflow guides the clinician through every step of the CNV interpretation process and is in complete agreeance with the authors of this paper on how this should look from a software perspective. Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. Today, we have been included in the esteemed Inc. 5000 list of rapidly growing American companies. Out of the 6 million business in the United States, Golden Helix has been honored with a spot in the annual list for the 2nd consecutive year... Read More

Golden Helix gets full marks in ClinGen’s list of Genomic Analysis Software Platforms

Golden Helix gets full marks in ClinGen’s list of Genomic Analysis Software Platforms 
 By Gabe Rudy
 VP of Product & Engineering

After vetting and reference checking participating vendors, ClinGen has now published its Genomic Analysis Software Platforms list. Beyond the minimal requirements, there were three additional achievements possible for software vendors. We are pleased to say that we are currently the only software vendor on this list to meet the requirements for all three of these additional achievements… Read More

SVS 8.9.0 Release Notes

SVS 8.9.0 Release Notes By James Grover
Senior Software Engineer

SVS 8.9.0 was released on August 19th and features a new GBLUP by Bin feature and a new utility to find the LD scores of markers and categorize them into bins, along with several mixed-model upgrades and many other upgrades, fixes, and polishes… Read More

CEO Corner
Andreas Scherer, PhD
August was a special month for our company. We were recognized as one of the fastest-growing private companies in the United States for the second consecutive year. This growth is purely based on our team's focus on customer success and satisfaction. I would like to thank the entire Golden Helix team for all the creativity, dedication, and attention to detail that is necessary to accomplish this result. Our number one priority is to listen to our clients' needs; converting those insights into products that support our clients in their daily clinical and research work. This award would not have been possible without the incredible loyalty of our customer base. On behalf of the entire Golden Helix team, I would like to thank all of our customers and partners for their support over the years. We are looking forward to continuing this momentum with exciting updates for the remainder of 2020 and beyond.
Upcoming Webcast

VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines for CNVs 
September 9, 2020 | 12:00 PM Eastern

As CNV detection has become widely adopted as a component of NGS testing, the demand has grown for an interpreting framework specific to CNVs in the context of rare and inherited disorders. Earlier this year, a ClinGen working group in collaboration with ACMG, published new guidelines for the interpreting and reporting of CNVs detected by NGS. We at Golden Helix have been hard at work expanding VSClinical to incorporate these new scoring and evaluation criteria for the interpretation and clinical reporting of CNVs alongside small variants in our popular guided workflow for following the ACMG guidelines. Please join us in this webinar as we preview the upcoming release of VarSeq with this major development.

Register
Recent Case Study

We recently shared a case study with Dr. Jeffrey Rosenfeld, Assistant Professor of Pathology and Laboratory Medicine and Manager of the Biomedical Informatics Shared Resource at the Rutgers Cancer Institute of New Jersey:

Researching the Impact of HLA on COVID-19 Patients with SNP & Variation Suite

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.